Form 4: Revolution Medicines' General Counsel Sells Shares Under 10b5-1 Trading Plan

Jeff Cislini, General Counsel of Revolution Medicines, sold 2,041 shares of common stock on March 20, 2025, under a pre-arranged 10b5-1 trading plan.

Summary

• Jeff Cislini, the General Counsel of Revolution Medicines, sold 2,041 shares of the company's common stock on March 20, 2025.
• The sale was executed under a 10b5-1 trading plan adopted on March 20, 2024.
• The shares were sold at a weighted average price of $38.7105, with individual trades ranging from $38.49 to $38.91.
• Following the transaction, Cislini directly owns 57,723 shares of Revolution Medicines, including 54,195 restricted stock units.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it reports a routine stock sale under a pre-existing trading plan. It doesn't inherently indicate positive or negative sentiment towards the company's prospects.

Industry Context

Sales by company insiders are a common occurrence and are often pre-planned through 10b5-1 trading plans to avoid accusations of trading on material non-public information. The market typically views these sales in the context of the overall insider holdings and the reasons behind the trading plan.

Comparison to Industry Standards

• Insider sales are a regular part of executive compensation, especially in publicly traded companies.
• The use of 10b5-1 trading plans is a standard practice to ensure compliance with insider trading regulations, similar to practices at companies like Amgen, Gilead, and Vertex.
• The volume of shares sold is relatively small compared to the total outstanding shares of Revolution Medicines, which is typical for routine sales by executives.

Stakeholder Impact

• The sale of shares by an executive could be perceived negatively by some shareholders, but the existence of a 10b5-1 trading plan mitigates this concern.

Key Dates

Keywords

Revolution Medicines, RVMD, Jeff Cislini, General Counsel, Form 4, Stock Sale, 10b5-1 Trading Plan, Insider Trading